Roivant Sciences (ROIV) Projected to Post Earnings on Thursday

Roivant Sciences (NASDAQ:ROIV - Get Free Report) is expected to post its Q4 2025 quarterly earnings results before the market opens on Thursday, May 29th. Analysts expect Roivant Sciences to post earnings of ($0.16) per share and revenue of $62.17 million for the quarter.

Roivant Sciences Stock Down 0.6%

Shares of ROIV stock traded down $0.07 during mid-day trading on Friday, reaching $10.87. The stock had a trading volume of 2,442,270 shares, compared to its average volume of 5,572,693. Roivant Sciences has a one year low of $8.73 and a one year high of $13.06. The firm has a market cap of $7.76 billion, a PE ratio of -72.46 and a beta of 1.23. The firm's 50 day simple moving average is $10.53 and its 200 day simple moving average is $11.05.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ROIV. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $10.95, for a total value of $1,095,000.00. Following the transaction, the chief operating officer now directly owns 1,077,197 shares in the company, valued at $11,795,307.15. The trade was a 8.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the transaction, the insider now owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,223,959 shares of company stock worth $13,450,035 over the last ninety days. Corporate insiders own 7.90% of the company's stock.

Institutional Investors Weigh In On Roivant Sciences

A hedge fund recently raised its stake in Roivant Sciences stock. Goldman Sachs Group Inc. raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 15.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,433,386 shares of the company's stock after acquiring an additional 324,764 shares during the quarter. Goldman Sachs Group Inc. owned about 0.34% of Roivant Sciences worth $24,553,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 64.76% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.